Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Call for Britain to over-ride patents on Roche cancer drug

A group of patients and campaigners has called on Britain’s health minister to over-ride patents protecting Roche’s expensive breast cancer drug Kadcyla to allow for the import or manufacture of cut-price copies.   The move shows the growing pricing pressure on drug companies on both sides of the Atlantic, especially in the field of cancer […]

Read More »

Novartis launches portfolio for low and low-middle-income countries

Novartis AG launched a portfolio of 15 medicines to treat chronic diseases in low- and low-middle-income countries, the drugmaker said in a statement on Thursday.   The Basel-based company said ‘Novartis Access’ will be launched first in Kenya, Ethiopia and Vietnam, with expansion to eventually include 30 countries. Novartis said the portfolio addresses cardiovascular diseases, […]

Read More »

Veritas Genetics Receives European CE Mark Approval for myBRCA Genetic Test for Hereditary Breast and Ovarian Cancer

BOSTON, Aug. 24, 2015 /PRNewswire/ —¬†Boston-based Veritas Genetics, a pioneer in accessible genetic screening for disease prevention and early detection, received its first European CE mark approval for the company’s hereditary breast and ovarian cancer genetic screening test, myBRCA. Veritas introduced myBRCA, which sequences BRCA1 and BRCA2 genes using proprietary gene-targeting technology and Next Generation […]

Read More »

Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talazoparib (BMN 673), a Potent PARP Inhibitor, From BioMarin

Talazoparib Is a Highly-Potent PARP Inhibitor in Phase 3 Development for the Treatment of BRCA-Mutated Breast Cancer; Clinical Activity Observed in Multiple Oncology Opportunities With Potential for Monotherapy or Combination Therapy With Standard of Care Oncology Treatments; Transaction Price of $410 Million Upfront, Up to $160 Million in Milestones and Mid-Single Digit Royalties SAN FRANCISCO, […]

Read More »

BioMarin Sells Phase III Breast Cancer Drug to Medivation for $570 Million

San Francisco-based Medivation, Inc. (MDVN), and San Rafael, Calif.-based BioMarin Pharmaceutical Inc. (BMRN) announced today that they have signed a deal for Medivation to buy all worldwide rights to talazoparib, formerly called BMN 673, for breast cancer treatment. Medivation will take over all research, development, regulatory and commercial activities.   Medivation will pay BioMarin $410 […]

Read More »

Esperance Pharmaceuticals, Inc. Announces Strategic Alliance With MD Anderson Cancer Center

BATON ROUGE, La., Aug. 24, 2015 /PRNewswire/ —¬†Esperance Pharmaceuticals Inc. today announced that it has entered into a strategic alliance agreement with MD Anderson Cancer Center to accelerate the clinical development of its lead anti-cancer candidate EP-100 for the treatment of ovarian cancer and to collaborate on preclinical studies of EP-100 as a treatment for […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom